Stephanie K. Dougan, MD, assistant professor, Dana-Farber Cancer Institute and Harvard Medical School, discusses the idea of augmenting T cell immunity in tumors that are poorly immunogenic, such as pancreatic cancer.

Related Content

Regorafenib Plus TAS-102 Demonstrates Clinically Meaningful Disease Control in mCRC

January 27, 2020 04:30am

By Wayne Kuznar

Microsatellite Instability Serves as a Predictive Biomarker of Response to Pembrolizumab

January 26, 2020 03:31am

By Joseph Chao, MD

Adding Dietary Supplements to Treatment Impacts Outcomes in Unresectable Pancreatic Cancer

January 25, 2020 05:00am

By Danielle Ternyila

Durable Responses Achieved With Triplet Combination in Gastric Cancer

January 25, 2020 03:00am

By Wayne Kuznar